Joji Mori
Overview
Explore the profile of Joji Mori including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
11
Citations
101
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Impact of the quality of resected thyroid cancer tissue sample on next-generation sequencing testing
Hatanaka K, Nakamura K, Katoh R, Ito K, Hirokawa M, Miyauchi A, et al.
Pathol Int
. 2024 Jan;
74(2):77-86.
PMID: 38226479
Activating rearranged during transfection (RET) proto-oncogene alterations can be identified using next-generation sequencing (NGS) of tumor DNA/RNA. We assessed factors associated with NGS (Oncomine Dx Target Test [ODxTT]) success for...
2.
Nishio M, Ohe Y, Ohashi K, Toyozawa R, Satouchi M, Sekine N, et al.
Gan To Kagaku Ryoho
. 2022 Jul;
49(6):669-675.
PMID: 35799394
Purpose: Selpercatinib is a highly selective, potent, rearranged during transfection(RET)inhibitor. A global, multicenter, open-label, phase 1/2 study of selpercatinib(LIBRETTO-001, NCT03157128)has been ongoing since 2017. We evaluated the data of Japanese...
3.
Mitani S, Chen Y, Inoue K, Mori J, Gao L, Long A, et al.
Gan To Kagaku Ryoho
. 2021 Nov;
48(11):1381-1387.
PMID: 34795131
Aim: We evaluated the safety and potential clinical impact of shortened ramucirumab infusion in Japanese patients from clinical studies. Methods: Multivariate logistic regression analysis was used to assess any association...
4.
Takahashi M, Tokunaga E, Mori J, Tanizawa Y, van der Walt J, Kawaguchi T, et al.
Breast Cancer
. 2021 Oct;
29(1):174-184.
PMID: 34661821
Background: This was a Japanese subpopulation analysis of MONARCH 3, a randomized, double-blind, placebo-controlled phase 3 study of abemaciclib plus nonsteroidal aromatase inhibitors (NSAIs) for initial therapy for advanced breast...
5.
Inoue K, Masuda N, Iwata H, Takahashi M, Ito Y, Miyoshi Y, et al.
Breast Cancer
. 2021 Apr;
28(5):1038-1050.
PMID: 33797023
Background: This was a Japanese subpopulation analysis of MONARCH 2, a double-blind, randomized, placebo-controlled, phase 3 study of abemaciclib plus fulvestrant in patients with hormone receptor-positive, human epidermal growth factor...
6.
Doi T, Tajimi M, Mori J, Asou H, Inoue K, Benhadji K, et al.
Invest New Drugs
. 2020 Sep;
39(2):469-476.
PMID: 32939607
Background This phase 1, single-center, nonrandomized, single-arm, open-label, dose-escalation study, evaluated the tolerability of crenigacestat, a γ-secretase inhibitor as an oral Notch inhibitor in Japanese patients with advanced solid tumors....
7.
Yonemori K, Kodaira M, Satoh T, Kudo T, Takahashi S, Nakano K, et al.
Cancer Sci
. 2018 Oct;
109(12):3962-3970.
PMID: 30353601
Olaratumab, a monoclonal antibody targeting human platelet-derived growth factor receptor α, plus doxorubicin significantly improved overall survival in patients with advanced soft-tissue sarcoma (STS) in a prior phase 1b/2 randomized...
8.
Fujiwara Y, Tamura K, Kondo S, Tanabe Y, Iwasa S, Shimomura A, et al.
Cancer Chemother Pharmacol
. 2016 Jun;
78(2):281-8.
PMID: 27312735
Purpose: To confirm the safety and tolerability, evaluate the pharmacokinetics (PK), and investigate the antitumor activity of abemaciclib in Japanese patients with advanced cancer. Methods: We conducted a non-randomized, single-arm,...
9.
Mori J, Kano Y
Pharm Stat
. 2015 Jul;
14(6):464-70.
PMID: 26214841
The crossover trial design (AB/BA design) is often used to compare the effects of two treatments in medical science because it performs within-subject comparisons, which increase the precision of a...
10.
Mori J, Kano Y, Yoshizaki M, Fukinbara S
Stat Med
. 2013 Sep;
32(29):5091-105.
PMID: 24038422
Medical diagnostic tests must enjoy appropriate validity and high reliability in order to qualify as adequate assessment tools. Without a gold standard test, available medical diagnostic tests are not perfect;...